Personalis shows promise in cancer detection but is years away from profitability. Read why PSNL stock is rated a hold with ...

As Alnylam Pharmaceuticals approaches its highly anticipated March 23 FDA decision date for a potential expansion of Amvuttra ...

Blueprint Medicines (BPMC) sees strong AYVAKIT growth, 2025 revenue guidance at $680M-$710M. Discover insights on their market expansion & $2B 2030 vision.

TD Cowen analyst Yaron Werber raised the firm’s price target on Ascendis Pharma (ASND) to $162 from $153 and keeps a Buy rating on the shares.

U.S. stocks recently experienced a downturn as inflation data came in hotter than expected, leading to increased Treasury yields and concerns over the Federal Reserve's monetary policy. In such a ...